Personalizing NSCLC: The Optimal Applicability of NGS and Liquid Biopsy

Personalizing NSCLC: The Optimal Applicability of NGS and Liquid Biopsy

Personalizing NSCLC: The Optimal Applicability of NGS and Liquid Biopsy

Are you aware of the transformations happening in the diagnostic approach and treatment of advanced non-small cell lung cancer? Tune in to keep up!

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mark Socinski, MD

    Executive Medical Director
    AdventHealth Cancer Institute
    Orlando, FL

    Consulting Fees: AstraZeneca, Blueprint, BMS, Genentech, Guardant Health, G1 Therapeutics, Inc., Janssen, Jazz Pharmaceuticals, Lilly, Regeneron, Sanofi
    Research: AstraZeneca, BeiGene, Cullinan Oncology, Daiichi Sankyo, Genentech, Mirati Therapeutics, Inc., Novartis, Pfizer, Spectrum Pharmaceuticals

    J. Marie Suga, MD, MPH
    Kaiser Permanente Vallejo
    Vallejo, CA

    Research: Alpha Oncology, Apollomics, Arcus, BMS, Cascadian, Genentech, Loxo Oncology, Mirati Therapeutics, Inc., Puma, Seattle Genetics, Spectrum Pharmaceuticals

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the optimal use of genetic testing strategies to identify patients with NSCLC harboring newly identified actionable targets
    • Explain how the results of NGS and liquid biopsy can assist with therapy selection in patients with NSCLC harboring MET mutations and EGFR exon 20 insertions
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, pulmonologists, pathologists, oncology nurse practitioners, physician assistants, oncology nurses, and oncology pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free